secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0000059478-25-000251
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand
--------------------------------------------------------------------------------

- Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.
- Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.
- Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.
- Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.
- U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/0000059478-25-000251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/lly-20251030.htm
  HTML page:      https://secwatch.observer/filing/0000059478-25-000251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer